Research ArticleCANCER IMMUNOLOGY

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

See allHide authors and affiliations

Science Immunology  09 Aug 2019:
Vol. 4, Issue 38, eaav6473
DOI: 10.1126/sciimmunol.aav6473

Article Information

vol. 4 no. 38

PubMed: 
Published By: 
History: 
  • Received October 6, 2018
  • Revision received March 5, 2019
  • Accepted July 10, 2019
  • .

Author Information

  1. Zhida Liu1,*,
  2. Chuanhui Han1,*,
  3. Chunbo Dong1,
  4. Aijun Shen1,
  5. Eric Hsu1,2,
  6. Zhenhua Ren1,
  7. Changzheng Lu1,
  8. Longchao Liu1,
  9. Anli Zhang1,
  10. Casey Timmerman1,2,
  11. Yang Pu1,
  12. Yang Wang1,
  13. Mingyi Chen1,
  14. Jian Qiao1 and
  15. Yang-Xin Fu1,2,
  1. 1Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75235, USA.
  2. 2Department of Immunology, UT Southwestern Medical Center, Dallas, TX 75235, USA.
  1. Corresponding author. Email: Yang-Xin.Fu{at}UTSouthwestern.edu
  • * These authors contributed equally to this work.

Altmetric

Article usage

Article usage: August 2019 to December 2019

AbstractFullPdf
Aug 2019479367761286
Sep 2019110514885
Oct 20196015232
Nov 20192324822
Dec 2019111108

Stay Connected to Science Immunology